Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
AssigneeOrion Corporation
InventorOskari Karjalainen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved process for the preparation of 4H-pyranone structured CYP11A1 inhibitors such as 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (1A) and key intermediates thereof such as 2-(chloromethyl)-5-hydroxy-4H-pyran-4-one (II), 5-hydroxy-2-(isoindolin-2-ylmethyl)-4H-pyran-4-one (III), (1-(methylsulfonyppiperidin-4-yHmethyl methane sulfonate (V) and (1-(methyl-sulfonyppiperidin-4-yHmethyl 4-methylbenzene fonate (V″). CYP11A1 inhibitors are useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.
Claims43
A process for the preparation of a compound of formula (1A) or a pharmaceutically acceptable salt thereof
- comprising the steps of either
- a) reacting a compound of formula (III)
- with a compound of formula (V)
- wherein LG is a leaving group selected from a mesyl or a tosyl group, in sulfolane in the presence of cesium carbonate;
- b) adding acetone and water to the mixture;
- and
- c) isolating the compound of formula (1A), and optionally converting it to its pharmaceutically acceptable salt;
- or
- a′) reacting a compound of formula (III)
- with a compound of formula (V)
- wherein LG is a leaving group selected from a mesyl or a tosyl group,
- in dimethyl sulfoxide or dimethyl formamide in the presence of cesium carbonate and tris[2-(2-methoxyethoxy)ethyl]amine);
- b′) adding isopropanol and water to the mixture;
- and
- c′) isolating the compound of formula (1A), and optionally converting it to its pharmaceutically acceptable salt.
A process for the preparation of a compound of formula (III)
- comprising the steps of either
- a) reacting a compound of formula (II)
- with isoindoline hydrochloride in water in the presence of potassium hydroxide;
- b) transferring the reaction mixture of step a) into a mixture of acetone and acetic acid;
- and
- c) isolating the compound of formula (III);
- or
- a′) reacting a compound of formula (II)
- with isoindoline hydrochloride in dimethyl sulfoxide in the presence of N,N-diisopropylethylamine;
- b′) adding acetonitrile and water to the mixture;
- and
- c′) isolating the compound of formula (III).
A process for the preparation of a compound of formula (II)
- comprising the steps of
- a) reacting a compound of formula (I)
- with thionyl chloride in acetonitrile;
- b) adding water;
- and
- c) isolating the compound of formula (II).
A process for the preparation of a compound of formula (V′)
- comprising the steps of
- a) reacting a compound of formula (IV)
- with methanesulfonyl chloride in acetonitrile-pyridine solvent;
- b) adding water and acetic acid to the mixture;
- and
- c) isolating the compound of formula (V′).
A process for the preparation of a compound of formula (V″)
- comprising the steps of
- a) reacting a compound of formula (IV)
- with chlorotrimethylsilane to obtain compound of formula (IVb)
- b) reacting the compound of formula (IVb) with methanesulfonyl chloride to obtain a compound of formula (IVc)
- c) treating the compound of formula (IVc) with p-toluenesulfonic acid in the presence of methanol to obtain a compound of formula (IVd)
- and
- d) reacting the compound of formula (IVd) with p-toluenesulfonyl chloride to obtain the compound of formula (V″).
A process for the preparation of a compound of formula (1A) or a pharmaceutically acceptable salt thereof
- comprising the steps of either
- a) reacting a compound of formula (II)
- with isoindoline hydrochloride in water in the presence of potassium hydroxide;
- b) transferring the reaction mixture of step a) into a mixture of acetone and acetic acid;
- and
- c) isolating the compound of formula (III);
- or
- a′) reacting a compound of formula (II)
- with isoindoline hydrochloride in dimethyl sulfoxide in the presence of N,N-diisopropylethylamine;
- b′) adding acetonitrile and water to the mixture;
- and
- c′) isolating the compound of formula (III);
- d) either reacting a compound of formula (III)
- with a compound of formula (V)
- wherein LG is a leaving group selected from a mesyl or a tosyl group,
- in sulfolane in the presence of cesium carbonate;
- e) adding acetone and water to the mixture;
- and
- f) isolating the compound of formula (1A), and optionally converting it to its pharmaceutically acceptable salt;
- or
- d′) reacting a compound of formula (III)
- with a compound of formula (V)
- wherein LG is a leaving group selected from a mesyl or a tosyl group,
- in dimethyl sulfoxide or dimethyl formamide in the presence of cesium carbonate and tris[2-(2-methoxyethoxy)ethyl]amine);
- e′) adding isopropanol and water to the mixture;
- and
- f′) isolating the compound of formula (1A), and optionally converting it to its pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.